The arguments in favor of streamlining biosimilar development are many, and support for it is broad, including regulators, biosimilar makers (of course), scientists, and other stakeholders. We’ve published several posts since 2021 on the need to reduce or eliminate the reliance on comparative clinical trials for biosimilar approval. See the following for a sample: Well, … Continue reading Compelling Arguments for Streamlining Biosimilar Development